Clinical Trial Update: A Clinical Study of B007 in the Treatment of Pemphigus. [Phase 2, Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 2/3 clinical study of B007 for pemphigus that is currently recruiting. Pemphigus is an autoimmune blistering disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus

Drugs mentioned

• B007

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Pemphigus | Phase 2, Phase 3 | Status: RECRUITING